Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis

Lizak N., Malpas C. B., Sharmin S., Havrdova E. K., Horakova D., Izquierdo G., ...Daha Fazla

JAMA NEUROLOGY, cilt.77, sa.11, ss.1398-1407, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 77 Sayı: 11
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1001/jamaneurol.2020.2453
  • Dergi Adı: JAMA NEUROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Psycinfo
  • Sayfa Sayıları: ss.1398-1407
  • Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Question Are clinical and demographic factors associated with the rate at which disability accumulates in secondary progressive multiple sclerosis, and is immunotherapy associated with a slower accumulation of disability among patients with active secondary progressive multiple sclerosis? Findings In this cohort study of 1621 patients with secondary progressive multiple sclerosis, relapses during the secondary progressive disease stage were associated with a faster rate of disability accumulation. Immunotherapies were associated with reductions in disability accumulation among patients who experienced superimposed relapses during the course of secondary progressive disease, and patients with active secondary progressive multiple sclerosis who were receiving sustained immunotherapy were less likely to become wheelchair-dependent than those who were not receiving immunotherapy. Meaning The study's findings suggest that disease-modifying therapies are associated with a slower rate of disability accumulation in patients with active secondary progressive multiple sclerosis.